Pitolisant

Drug Profile

Pitolisant

Alternative Names: BF 2.649; BF-2649; Pitolisant hydrochloride; Tiprolisant; Wakix

Latest Information Update: 17 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioprojet; Ferrer
  • Developer Bioprojet
  • Class Nootropics; Piperidines; Sleep disorder therapies
  • Mechanism of Action Histamine H3 receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Narcolepsy
  • Phase III Hypersomnia
  • Phase I Drug abuse
  • No development reported Attention-deficit hyperactivity disorder
  • Discontinued Epilepsy; Obesity

Most Recent Events

  • 15 Mar 2017 Phase-I clinical trials in Drug abuse (In volunteers) in Canada (PO) (NCT03152123)
  • 13 Feb 2017 The Scottish Medicines Consortium does not recommend pitolisant for the treatment of Narcolepsy for use within NHS Scotland
  • 11 Jan 2017 Bioprojet withdraws the phase II PoC Alcohol trial before enrolment due to the sponsor decision for Alcoholism in Bulgaria (NCT02800083)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top